Jump to Main Content

Press Releases

With a Focus on Case Studies ASH Meeting to Address Challenging Patient Care Questions

Meeting to Feature Unique “How I Treat” Model, Will Showcase Evidence-Based Treatment Approaches 

This weekend, the American Society of Hematology (ASH), the world’s largest professional organization dedicated to the causes and treatments of blood disorders, will bring leading experts in hematologic malignancies to Chicago to share the most cutting-edge practices for treating different hematologic malignancies.

Through a series of dynamic, case-based discussions, international experts will help attendees of the ASH Meeting on Hematologic Malignancies understand how to best deploy the latest treatment strategies and agents to enhance care for patients with cancers of the blood, including leukemia, lymphoma, and myeloma. These 19 “How I Treat” sessions—modeled after the popular series in ASH’s journal Blood—will showcase speakers’ evidence-based treatment approaches, and will include talks around standards of care, unique disease complications, and responsible methods for integrating new drugs into practice. Meeting attendees are encouraged to take advantage of the small-meeting environment to ask the experts about challenges that they have faced in treating patients to further the discussion.

“What makes this meeting so unique,” said meeting co-chair Martin Tallman, MD, of Memorial Sloan-Kettering Cancer Center in New York City, “is that conversation does not end with each session. From coffee breaks to our popular lunch with the experts, in the hallways, and during receptions, attendees are encouraged to seek answers on specific cases directly from the faculty in both formal and informal settings.”

ASH President-Elect and meeting co-chair Kenneth Anderson, MD, of the Dana Farber Cancer Institute in Boston added, “One of the best reasons to attend the ASH Meeting on Hematologic Malignancies is the interaction—there has been time built in for one-to-one interaction with experts, allowing attendees to come away with first-hand knowledge of new strategies that they can implement the moment they return to the clinic.”

In addition to the “How I Treat” sessions, this meeting will preview the latest clinical research to be released prior to the 58th ASH Annual Meeting and Exposition in San Diego. Six oral abstract presentations and 62 posters will highlight the latest advances in hematologic malignancies, including a possible therapeutic treatment for select cases of acute myeloid leukemia, a proof-of-principle for improving cancer immunotherapies, and a new standard-of-care model for the treatment of multiple myeloma. Additional research will be featured through poster session presentations.

“With the scientific landscape constantly shifting as new discoveries continuously come to the fore, this meeting really helps clinicians not only learn the latest and greatest advancements, but also to interactively work out the best ways to bring this science directly to their patients,” said Joseph M. Connors, MD, of the Vancouver Clinic and British Columbia Cancer Agency — the meeting’s third co-chair.

The ASH Meeting on Hematologic Malignancies will take place September 16–17 in Chicago’s Fairmont Millennium Park Hotel. The complete meeting program, as well as a collection of “How I Treat” preview videos are available on the ASH website. Up-to-the-minute meeting information can also be found on Twitter by following @ASH_Hematology and #ASHMHM16.

The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.


Stephen Fitzmaurice, American Society of Hematology
[email protected]; 202-552-4927